JP2024099628A5 - - Google Patents

Download PDF

Info

Publication number
JP2024099628A5
JP2024099628A5 JP2024066182A JP2024066182A JP2024099628A5 JP 2024099628 A5 JP2024099628 A5 JP 2024099628A5 JP 2024066182 A JP2024066182 A JP 2024066182A JP 2024066182 A JP2024066182 A JP 2024066182A JP 2024099628 A5 JP2024099628 A5 JP 2024099628A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
concentration
mannitol
excipient
lyophilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024066182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024099628A (ja
Filing date
Publication date
Priority claimed from CN201410002665.6A external-priority patent/CN104758922A/zh
Application filed filed Critical
Publication of JP2024099628A publication Critical patent/JP2024099628A/ja
Publication of JP2024099628A5 publication Critical patent/JP2024099628A5/ja
Pending legal-status Critical Current

Links

JP2024066182A 2014-01-03 2024-04-16 ニューレグリン調合剤の処方 Pending JP2024099628A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410002665.6A CN104758922A (zh) 2014-01-03 2014-01-03 纽兰格林制剂的配方
CN201410002665.6 2014-01-03
JP2020082456A JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方
JP2022105452A JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022105452A Division JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方

Publications (2)

Publication Number Publication Date
JP2024099628A JP2024099628A (ja) 2024-07-25
JP2024099628A5 true JP2024099628A5 (https=) 2024-10-08

Family

ID=53493186

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016544419A Active JP6703483B2 (ja) 2014-01-03 2014-12-17 ニューレグリン調合剤の処方
JP2020082456A Active JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方
JP2022105452A Active JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方
JP2024066182A Pending JP2024099628A (ja) 2014-01-03 2024-04-16 ニューレグリン調合剤の処方

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016544419A Active JP6703483B2 (ja) 2014-01-03 2014-12-17 ニューレグリン調合剤の処方
JP2020082456A Active JP7100083B2 (ja) 2014-01-03 2020-05-08 ニューレグリン調合剤の処方
JP2022105452A Active JP7479068B2 (ja) 2014-01-03 2022-06-30 ニューレグリン調合剤の処方

Country Status (10)

Country Link
US (3) US10702585B2 (https=)
EP (2) EP3821904B1 (https=)
JP (4) JP6703483B2 (https=)
KR (3) KR20160105443A (https=)
CN (4) CN104758922A (https=)
AU (1) AU2014375637A1 (https=)
BR (1) BR112016015660A2 (https=)
CA (1) CA2935607A1 (https=)
RU (1) RU2738158C2 (https=)
WO (1) WO2015101182A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104758922A (zh) * 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液
EP4076697A4 (en) * 2019-12-16 2024-01-03 Seagen Inc. QUANTIFICATION OF EXCIPIENTS USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
WO1998035036A1 (en) 1997-02-10 1998-08-13 Genentech, Inc. Heregulin variants
JP2001519400A (ja) 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク. ニューレグリン使用を含む治療法
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20030016233A (ko) 2000-02-28 2003-02-26 디코드 제네틱스 이에이치에프 사람 정신분열증 유전자
IL153052A0 (en) * 2000-05-23 2003-06-24 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7375185B2 (en) 2000-09-12 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
DE10124387A1 (de) * 2001-05-18 2002-11-28 Basf Ag Hydrophob modifizierte Polyethylenimine und Polyvinylamine zur Antiknitterausrüstung von cellulosehaltigen Textilien
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
CA2506630A1 (en) 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Heart failure gene determination and therapeutic screening
EP1631268A2 (en) 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
GB0413005D0 (en) 2004-06-11 2004-07-14 Coletica Ligand
US20080213395A1 (en) 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
WO2006081190A2 (en) * 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
ATE502998T1 (de) 2006-07-07 2011-04-15 Procter & Gamble Waschmittelzusammensetzungen
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ.ホフマン−ラ ロシュ アーゲー 心不全の評価におけるigfbp−7の使用
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
CN101310766B (zh) 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
US20110212108A1 (en) 2008-05-09 2011-09-01 The Regents Of The University Of California Neuregulin/erbb signaling and integrin
CN102159236A (zh) 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
JP2012509908A (ja) 2008-11-28 2012-04-26 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
EP3087998B1 (en) 2009-06-09 2019-09-04 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin based methods for treating heart failure
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
PL2544537T3 (pl) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Pozajelitowe preparaty antybiotyków makrolidowych
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
CN104997803B (zh) 2010-07-22 2019-07-09 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物
CN102230084B (zh) * 2011-06-14 2013-01-23 东北大学 低品位含砷难浸金矿的包覆生物氧化预处理方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
EP2964249A1 (en) 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN110840895A (zh) 2013-07-23 2020-02-28 上海泽生科技开发股份有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Similar Documents

Publication Publication Date Title
JP2024099628A5 (https=)
JP2022130627A5 (https=)
ES2286868T3 (es) Composicion acuosa a base de hormana del crecimiento humana.
CN1523997B (zh) 稳定的白介素2
TWI593421B (zh) 凍乾的重組vwf調配物
KR100457485B1 (ko) 안정한 트란스글루타미나제 제형 및 이의 제조 방법
US20110269685A1 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
NO327302B1 (no) Lagringsstabil sammensetning, forseglet ror eller patron inneholdende nevnte sammensetning samt fremgangsmate for deres fremstilling
KR100705997B1 (ko) 안정화된 hgf 동결건조제제 및 그 제조방법
ES2224637T3 (es) Formulaciones deproteina.
US20240041977A1 (en) Annexin a1 n-terminal peptide formulations and methods
US20250215054A1 (en) Compositions and methods for treatment of fungal infections
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
JP2025121987A (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物
CN105451756A (zh) 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
US6497869B2 (en) Stabilized granulocyte colony stimulating factor
AU2014237111B2 (en) Recombinant factor VIII formulations
BR112012010392B1 (pt) composição e kit para o inibidor de alfa-1 proteinase
JPH06247872A (ja) 高濃度tcf製剤
US5861481A (en) Peptide lung surfactants and therapeutic combinations
IE903479A1 (en) Stabilized Leukocyte-Interferons
US12012440B2 (en) Compositions and methods for treatment of fungal infections
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
RU2025126931A (ru) СОСТАВЫ, ВКЛЮЧАЮЩИЕ ВАРИАНТЫ ПОЛИПЕПТИДА ActRIIa
JPH07291874A (ja) ヘパリン中和剤